|
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC). |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; Sanofi/Aventis |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen-Cilag; Sanofi/Aventis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Janssen Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Co-inventor on a patent filed by The University of Michigan and The Brigham and Women’s Hospital covering the diagnostic and therapeutic fields for ETS fusions in prostate cancer. The diagnostic field has been licensed to Gen-Probe. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Janssen; Janssen (I) |
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; Bayer; ESSA; Janssen-Cilag; Medivation; Millennium; Novartis; Pfizer; Ventana Medical Systems; Veridex |
Speakers' Bureau - Astellas Pharma; Janssen; Sanofi; Takeda; Ventana Medical Systems |
Research Funding - Arno Therapeutics (Inst); Innocrin Pharma (Inst); Janssen (Inst) |
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate. |
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Janssen; Janssen (I); Medivation; Pfizer; Ventana Medical Systems |
Other Relationship - Institute of Cancer Research |